Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gadolinium cation (3+) is the trivalent form of the element gadolinium, represented as Gd3+. It is not used directly as a drug but serves as the active component in various gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI). In these agents, Gd3+ is tightly chelated by organic ligands to reduce toxicity and facilitate safe intravenous administration. The primary mechanism of action involves shortening T1 relaxation times in MRI, thereby enhancing image contrast in tissues with abnormal vascularity or blood-brain barrier disruption. Free Gd3+ ions are highly toxic due to their interference with calcium-dependent biological processes; thus, they are always administered in chelated forms such as gadoteric acid or other macrocyclic/linear complexes[1][8]. The development and manufacturing of these agents involve companies specializing in rare earth elements and pharmaceutical-grade chemicals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gadolinium cation (3+).